EUVIMEDEUVIMED entdecken
Open Access

Immunomodulatory effects of HYCO-3, a dual action CO-releaser/Nrf2 activator

Goran Stegnjaić, Neda Nikolovski, Suzana Stanisavljević, Milica Lazarević, Miljana Momčilović, Roberta Foresti, Roberto Motterlini, Đorđe Miljković iD

Clinical and Experimental Immunology · 2025

DOI: 10.1093/cei/uxae100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Goran Stegnjaić und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Institute for Biological Research 'Siniša Stanković' - National Institute of Republic of Serbia, University of Belgrade, Be…. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Encephalomyelitis, Autoimmune, Experimental, Carbon Monoxide, Immunomodulating Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministry of Science, Technological Development, and Innovations, Republic of Serbia, SATT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HYCOs are hybrid molecules consisting of activators of the transcription factor Nrf2 conjugated to carbon monoxide (CO)-releasing moieties. These ‘dual action’ compounds (HYCOs) have been designed to mimic the activity of heme oxygenase-1 (HO-1), a stress inducible cytoprotective enzyme that degrades heme to CO which expression is regulated by Nrf2. HYCOs have recently shown efficacy in ameliorating experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. However, the mechanism(s) of action of HYCOs still remains to be fully investigated. Here, we assessed the effects of HYCO-3, a prototype of these hybrids, on myeloid-derived cells, microglial cells and T lymphocytes obtained from EAE-immunized mice. HYCO-3 exerted immunomodulatory effects on all the examined cell populations by inhibiting the generation of pro-inflammatory cytokines and nitric oxide, and downregulating antigen-presenting capacity of these cells. The observed effects support the view that HYCOs are promising candidates to be developed for the treatment of autoimmune and chronic inflammatory disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-E2-Related Factor 2Encephalomyelitis, Autoimmune, ExperimentalCarbon MonoxideImmunomodulating AgentsImmunologic FactorsAnimalsMiceNitric OxideMicrogliaHeme Oxygenase-1T-LymphocytesCytokinesMice, Inbred C57BLFemaleAntigen Presentation

Stichwörter der Autor:innen

EAEautoimmunityinflammationmultiple sclerosisneuroimmunology

Substanzen

NF-E2-Related Factor 2Carbon MonoxideNitric OxideHeme Oxygenase-1CytokinesNfe2l2 protein, mouseImmunomodulating AgentsImmunologic Factors

Autor:innen und Institutionen

  • Department of Immunology, Institute for Biological Research 'Siniša Stanković' - National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia.
  • Faculty of Health, University Paris Est-Créteil, INSERM, IMRB, Paris, France.

ORCID-Profile: Đorđe Miljković

Förderung

  • Ministry of Science, Technological Development, and Innovations, Republic of Serbia
  • SATT

Zitieren

APA

Stegnjaić, G., Nikolovski, N., Stanisavljević, S., Lazarević, M., Momčilović, M., Foresti, R., Motterlini, R., & Miljković, Đ. (2025). Immunomodulatory effects of HYCO-3, a dual action CO-releaser/Nrf2 activator. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae100

Vancouver

Stegnjaić G, Nikolovski N, Stanisavljević S, Lazarević M, Momčilović M, Foresti R, et al. Immunomodulatory effects of HYCO-3, a dual action CO-releaser/Nrf2 activator. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxae100

BibTeX
@article{Stegnjai2025,
  author = {Stegnjaić, Goran and Nikolovski, Neda and Stanisavljević, Suzana and Lazarević, Milica and Momčilović, Miljana and Foresti, Roberta and Motterlini, Roberto and Miljković, Đorđe},
  title = {Immunomodulatory effects of HYCO-3, a dual action CO-releaser/Nrf2 activator},
  journal = {Clinical and Experimental Immunology},
  year = {2025},
  doi = {10.1093/cei/uxae100}
}
Kostenlos starten →